Feb 23 (Reuters) - In a little-noticed move, Novartis last week settled a lawsuit by the estate of Henrietta Lacks, resolving claims that it profited from using her "immortal" cells without permission. The confidential deal doesn’t end the broader legal campaign by Lacks’ heirs. Litigation against other drugmakers that have relied on her cell lines to fuel biomedical research is heating up after a federal judge in Maryland last year refused to dismiss the claims as time-barred. Sign up here.